Eli Lilly Press Release (07/11/12)
Eli Lilly says that a compound used to treat the acute exacerbation of schizophrenia did not meet the primary endpoint of a recent clinical study. During that study, pomaglumetad methionil did not separate from placebo in the primary efficacy endpoint in either the overall or predefined genetic sub-population, based on the Positive and Negative Syndrome Scale (PANSS). This lack of separation was seen in both the 40 mg and 80 mg doses of pomaglumetad methionil. In addition, the study found that the active control risperidone failed to separate from placebo in both populations. However, the study did find that pomaglumetad methionil was generally well tolerated in those who took it. The study also did not produce any new safety findings compared with previous trials. Eli Lilly has yet to make a decision about the future development of pomaglumetad methionil, and is awaiting data from a second registration clinical trial and a Phase II study before it does so.

Read the complete article